08.03.18
United Kingdom
www.gsk.com
Sales: $3.1 billion oral care products. Corporate sales: $37.3 billion.
Key Personnel: Emma Walmsley, chief executive officer; Simon Dingemans, chief financial officer; Roger Connor, president, global manufacturing and supply; Brian McNamara, chief executive officer, GSK Consumer Healthcare; David Redfern, chief strategy officer; Karenann Terrell, chief digital and technology officer; Hal Barron, chief scientific officer and president, R&D.
Major Products: Oral care—Sensodyne, Polident/Corega, Parodontax, Biotene and Aquafresh.
New Products: Sensodyne Rapid Relief, Pronamel Strong & Bright, Polident Max Seal and Paradontax Complete Protection.
Comments: Corporate sales rose 8%. Oral health sales grew 11%, as Sensodyne posted a 12% increase in sales, with strong delivery in all regions following the roll out of next generation Sensodyne Rapid Relief and the launch of Pronamel Strong & Bright. Sales of Parodontax continued to grow strongly, reflecting double-digit performances in Europe and international markets, driven by a brand reset and increases in dentist recommendations, as well as the US launch in the first quarter. Denture care grew in mid-single digits with double-digit growth in emerging markets partly offset by slower consumption growth in the US and Germany.
For the first quarter of 2018, corporate sales fell 2% and consumer healthcare sales dipped 3%. Still, GSK noted that oral care sales had a good three-month performance, adding 2% on the strength of Sensodyne sales. Furthermore, sales of denture care and Paradontax grew in double-digits, thanks to increased dentist recommendations and the role out of Polident Max Seal and Paradontax Complete Protection.
www.gsk.com
Sales: $3.1 billion oral care products. Corporate sales: $37.3 billion.
Key Personnel: Emma Walmsley, chief executive officer; Simon Dingemans, chief financial officer; Roger Connor, president, global manufacturing and supply; Brian McNamara, chief executive officer, GSK Consumer Healthcare; David Redfern, chief strategy officer; Karenann Terrell, chief digital and technology officer; Hal Barron, chief scientific officer and president, R&D.
Major Products: Oral care—Sensodyne, Polident/Corega, Parodontax, Biotene and Aquafresh.
New Products: Sensodyne Rapid Relief, Pronamel Strong & Bright, Polident Max Seal and Paradontax Complete Protection.
Comments: Corporate sales rose 8%. Oral health sales grew 11%, as Sensodyne posted a 12% increase in sales, with strong delivery in all regions following the roll out of next generation Sensodyne Rapid Relief and the launch of Pronamel Strong & Bright. Sales of Parodontax continued to grow strongly, reflecting double-digit performances in Europe and international markets, driven by a brand reset and increases in dentist recommendations, as well as the US launch in the first quarter. Denture care grew in mid-single digits with double-digit growth in emerging markets partly offset by slower consumption growth in the US and Germany.
For the first quarter of 2018, corporate sales fell 2% and consumer healthcare sales dipped 3%. Still, GSK noted that oral care sales had a good three-month performance, adding 2% on the strength of Sensodyne sales. Furthermore, sales of denture care and Paradontax grew in double-digits, thanks to increased dentist recommendations and the role out of Polident Max Seal and Paradontax Complete Protection.
